Kidney Function and Immunotherapy — When You Have One Kidney

Most patients with cancer are not candidates for immunotherapy at all, and the number of kidneys you have is not what decides it. Eligibility comes from the cancer type, the stage and your medical history. Where immunotherapy does apply, one working kidney is rarely the reason it is withheld, and the dose is usually unchanged.

The reason is how these drugs leave the body. Immunotherapy of the checkpoint inhibitor class is made of large protein molecules. They are broken down the way the body breaks down other proteins. They are not filtered out and excreted by the kidney the way many chemotherapy drugs are.

That is why the published product information for this class does not set a dose reduction for mild or moderate reduction in kidney function. Chemotherapy is the opposite case. Several chemotherapy drugs are dose-adjusted or avoided as eGFR falls. Patients carry that expectation across from chemotherapy to immunotherapy, and it does not transfer.

What does change is the safety margin. With two kidneys, an episode of inflammation, a bout of vomiting or the wrong painkiller has spare capacity to fall back on. With one, the same event moves the numbers further and takes longer to recover from. That is the reason monitoring is tighter here, and the reason it is run as a protocol rather than left to symptoms.

Nothing on this page decides whether immunotherapy is suitable. That comes from the histology report, the stage, your kidney function and the rest of your medical history, read together by a medical oncologist.

No. Removing a kidney does not make immune nephritis more likely. The risk comes from the treatment, not from the number of kidneys. Immune-related nephritis is uncommon on checkpoint inhibitor treatment, and it is reported more often when two immunotherapy drugs are given together than with one alone.

Immune nephritis is inflammation of the filtering tissue of the kidney. It is caused by the same loosening of immune restraint that is meant to act on the tumour. It sits among the less common immune-related side effects. Skin and bowel reactions are seen far more often.

Timing is the part patients are rarely told. Nephritis usually appears later than a rash or loose motions, commonly after the first two to three months of treatment, and it can appear weeks after the last dose. It almost never announces itself. In most patients a rising creatinine on a routine blood test is the first and only sign.

There is a second reason the whole medicine list is reviewed at every visit. Anti-inflammatory painkillers and some acidity medicines are themselves recognised causes of the same kind of kidney inflammation. When creatinine rises during immunotherapy, the team has to separate the treatment from everything else you are taking. That is far easier when the list has been accurate from the first cycle.

What is genuinely different after a nephrectomy is the consequence, not the chance. That is an argument for finding it earlier, not for avoiding treatment that is otherwise indicated.

Creatinine, eGFR and urine protein at baseline, then before every cycle. The schedule is fixed, not symptom-driven. With one kidney the results are read against your own baseline rather than the laboratory's normal range, because a value that looks normal on paper can still be a real change for you.

If creatinine rises, the first step is review, not stopping. The team looks for the cause, may hold a cycle, and treats immune nephritis when that is what it proves to be. Do not start, stop or change any medicine at home on the strength of one blood result — tell the treating team instead.

Because for many patients it was not the standard at the time of surgery. Guideline bodies including NCCN and ESMO now place immunotherapy-based treatment ahead of the older first choices in advanced clear-cell kidney cancer, and immunotherapy has a defined role in bladder and other urological cancers. Several of those changes are recent.

Patients who have had a kidney removed are a large and very mixed group. Some had surgery for a cancer that never came back and need no drug treatment at all. Some are on routine follow-up. Some were started years ago on a treatment that current guidance would no longer choose first. The three groups need completely different answers, and they get mixed together in the same forum threads and WhatsApp groups.

There is also a group who were told, correctly at the time, that their kidney function ruled out further drug treatment. That advice was almost always about chemotherapy. It does not automatically carry across to immunotherapy, which the body handles differently.

None of this means a plan should change. It means the question is worth asking with the reports in front of an oncologist, rather than assuming the answer either way. The same shift happened in bladder cancer, set out in Immunotherapy for Bladder Cancer After BCG Fails; the counter-example, where immunotherapy is asked about constantly and applies to very few patients, is covered in Immunotherapy for Prostate Cancer: Why It Rarely Works.

Four things: fluids, painkillers, contrast scans and the medicine list. None of them make immunotherapy unsafe. All of them are easier to get right when they are agreed with the treating team at the start, rather than sorted out after a blood result has already moved.

• Fluids, especially through a Telangana summer — dehydration from heat, vomiting or loose motions lowers filtration before anything immune is involved. Agree a daily fluid target with the team; more is not automatically better if there is heart or blood-pressure disease.
• Painkillers — anti-inflammatory tablets sold over the counter for fever and body ache are hard on a single kidney and can inflame it themselves. Ask which painkiller is safe for you before you need one, not at 11pm.
• Contrast scans — response assessment usually needs contrast, so eGFR is checked beforehand and hydration is arranged around it. This imaging is coordinated at partner imaging centres, so carry your latest kidney reports to the appointment.
• Every other prescription — acidity, blood-pressure, diabetes and antibiotic medicines, and any Ayurvedic, homeopathic or herbal preparation, belong on the list you show the oncology team. The purpose is disclosure so a rising creatinine can be read correctly.
• What to report between cycles — passing much less urine, new ankle or leg swelling, sudden weight gain, or feeling unusually drowsy. Tell the treating team; do not wait for the next scheduled visit and do not change any medicine yourself.

Immunotherapy itself is given as day care at CION centres. A routine cycle does not need an overnight stay, and having one kidney does not change that.

• What immunotherapy costs in these cancers, and what schemes and insurance actually cover — Cost of Immunotherapy for Kidney and Bladder Cancer.
• If bladder treatment with BCG has stopped working, the options changed there too — Immunotherapy for Bladder Cancer After BCG Fails.
• The urological cancer where immunotherapy is asked about most and applies least — Immunotherapy for Prostate Cancer: Why It Rarely Works.
• How immunotherapy is delivered, monitored and paid for across our centres — Immunotherapy at CION Cancer Clinics.

Still unsure how any of this applies to your own kidney function? Book a free consultation and a medical oncologist will go through the reports with you.